Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Novo Nordisk A/S(NVO) Shareholders
08:45am, Tuesday, 02'nd Sep 2025
NEW YORK , Sept. 2, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
BRISTOL, England & LONDON & WASHINGTON--(BUSINESS WIRE)--Phasecraft, the world's leading quantum algorithms company, announces $34 million Series B to accelerate work on quantum computing applications
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
02:16am, Tuesday, 02'nd Sep 2025
NEW YORK , Sept. 2, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2025,
NEW YORK, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed
NVO's Wegovy vs. LLY's Tirzepatide: Who Leads in Heart Risk Reduction?
11:56am, Monday, 01'st Sep 2025
Novo Nordisk's Wegovy shows a stronger reduction in heart risks compared to Eli Lilly's tirzepatide in real-world data from the STEER study.
Wegovy trial result gives boost to Novo Nordisk amid U.S. market woes
09:05am, Monday, 01'st Sep 2025
Trial data released by Novo Nordisk showed a significant reduction in the risk of heart attack, stroke or death in certain patients on its blockbuster weight-loss treatment Wegovy, compared with drugs
Novo's Wegovy Beats Lilly's Zepbound for Heart Health, Study Finds. What It Means for Stocks.
06:39am, Monday, 01'st Sep 2025
The study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy are specific to semaglutide.
Novo Nordisk Says Wegovy Cuts Heart Risk by 57% Compared With Eli Lilly's Obesity Drug
03:30am, Monday, 01'st Sep 2025
The study used evidence gathered from patient experiences rather than a controlled trial, Novo said.
NEW YORK, Aug. 31, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2
Novo Nordisk's Wegovy cuts heart risk by 57% versus rival Lilly weight-loss drug in study
12:30pm, Sunday, 31'st Aug 2025
Novo Nordisk said on Sunday its blockbuster weight-loss drug Wegovy cut the risk of heart attack, stroke or death by 57% versus Eli Lilly's rival medicines Mounjaro and Zepbound in a real-world compar
Bagsværd, Denmark, 31 August 2025 – Novo Nordisk today presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC
Bagsværd, Denmark, 31 August 2025 – Novo Nordisk today presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC
BENSALEM, Pa., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded
NEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO). Such in
Denmark cuts growth forecast as Novo slowdown sparks reliance debate
08:37am, Friday, 29'th Aug 2025
Denmark's government has lowered its 2025 economic growth forecast to 1.4% from a previous projection of 3%, citing weaker prospects for pharmaceutical giant Novo Nordisk and new tariffs on Danish exp
